Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EGFR-TKI +/- Chemotherapy in EGFR+ NSCLC with Concurrent Mutations
NCT04552613Completed
- Sponsor
- The Fourth Affiliated Hospital of Zhejiang University School of Medicine
- Start
- Nov 2020
- Primary completion
- Sep 2023
- Modality
- DNA Intercalators/Alkylators
- Countries
- 1
01
Overview
Randomised, open-label trial of pemetrexed and carboplatin in non-small cell lung cancer (NSCLC) (2 arms), sponsored by The Fourth Affiliated Hospital of Zhejiang University School of Medicine. Primary endpoints: Progression-Free Survival at 3 years and Objective Response Rate at 3 years. Started Nov 2020; status: completed.
02
Drugs
pemetrexedcarboplatin
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT04552613.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04552613.